Eli Lilly (NY:LLY)

The third-quarter 2025 earnings season, largely drawing to a close in early November, has proven to be a dynamic and often surprising period for investors. While a significant majority of S&P 500...

Topics Government

Navigating the Volatility: Q3 2025 Earnings Season Delivers Both Cheers and Concerns

Today 10:25 EST

San Diego, CA – November 6, 2025 – Ligand Pharmaceuticals (NASDAQ: LGND) has recently captured the financial spotlight, with its stock hitting a remarkable 52-week high of $197.78 on November 6, 2025....

Topics Artificial Intelligence Economy Stocks

Ligand Pharmaceuticals Soars to New Heights: A Deep Dive into its 52-Week High

Today 10:13 EST

Eli Lilly, Novo Nordisk Or A Dark Horse: Which Obesity-Drug Stock Are Retail Traders Most Bullish On Over Next 5 Years?

Topics Intellectual Property

Today 3:32 EST

Whether you're looking for AI stocks or dividend stocks, there is something for everyone in this list.

My 6 Top-Ranked Stocks to Buy Right Now in November

Today 9:30 EST

Trump Administration's Weight-Loss Drug Deal Is Sending This Novo Nordisk Rival Surging: Momentum Score Spikes

Topics Artificial Intelligence

Today 5:13 EST

A leading pharmaceutical stock that goes head-to-head against Novo Nordisk A/S is surging amid a potential deal with the Trump administration.

Via Benzinga

Topics Government

Dow Jumps Over 200 Points: Investor Sentiment Improves, Fear & Greed Index Remains In 'Extreme Fear' Zone

Today 1:58 EST

The CNN Fear & Greed Index eased, but remained in Extreme Fear zone on Wed. Stocks rose on solid earnings & speculation of Fed rate cut.

Via Benzinga

Topics Economy Stocks

1 Mid-Cap Stock for Long-Term Investors and 2 We Question

November 05, 2025

Mid-cap stocks often strike the right balance between having proven business models and market opportunities that can support $100 billion corporations. However, they face intense competition from...

Eli Lilly And Novo Nordisk Ignite Bullish Retail Frenzy Ahead Of TrumpRx Deals To Slash Prices For Weight-Loss Drugs

November 04, 2025

Specialty pharmaceutical company ANI Pharmaceuticals (NASDAQ:ANIP) will be reporting results this Friday before the bell. Here’s what to look for.

ANI Pharmaceuticals (ANIP) To Report Earnings Tomorrow: Here Is What To Expect

November 05, 2025

Investing in pharmaceutical companies with diversified revenue bases and strong R&D pipelines could be a lucrative strategy.

Topics Artificial Intelligence

2 Reasons I'm Keeping My Eye on Eli Lilly Stock Right Now

November 05, 2025

Microsoft Gets $135 Billion OpenAI Stake

November 05, 2025

In the intricate tapestry of global financial markets, few metrics hold as much sway and immediate relevance as market capitalization. Representing the total dollar value of a company's outstanding...

The Shifting Sands of Valuation: Understanding Market Cap Movers in a Dynamic Market

November 05, 2025

The Resilient Market: Investor Optimism and the Enduring Power of "Dip-Buying" in November 2025

Topics Artificial Intelligence Bankruptcy Earnings

November 05, 2025

As November 2025 unfolds, the financial markets are characterized by a palpable sense of cautious optimism, a sentiment largely underpinned by the continued prevalence and success of "dip-buying"...

Tech Titans and Pharma Powerhouses Drive Market Volatility: AMD, Palantir, Micron, and Eli Lilly in Focus

Topics Artificial Intelligence ETFs Economy

November 05, 2025

As of November 5, 2025, the financial markets experienced a day of notable activity, with several key players across the technology and pharmaceutical sectors capturing investor attention. Advanced...

The burgeoning market for obesity and diabetes treatments, particularly GLP-1 receptor agonists, is witnessing a dramatic divergence in fortunes among its leading players. As of November 5, 2025, Novo...

Topics Artificial Intelligence Economy

Obesity Drugmakers Face Shifting Tides: Novo Nordisk Plunges While Eli Lilly Soars

November 05, 2025

Market Recovers from Tariff Turmoil: Dow, S&P 500, and Nasdaq Stage Resilient Rebound Amid Shifting Economic Winds

Topics Economy

November 05, 2025

The U.S. financial markets have demonstrated remarkable resilience in 2025, staging a significant rebound after experiencing a sharp selloff earlier in the year. The Dow Jones Industrial Average, S&P...

Wall Street bounced back Wednesday after Tuesday's sharp selloff in AI-driven stocks, as investors bought the dip amid solid corporate earnings and growing signs that the Federal Reserve may be nearing...

Topics Artificial Intelligence Economy Government

Stocks Rebound, Eli Lilly Jumps To 14-Month Highs: What's Moving Markets Wednesday?

November 05, 2025

Via Benzinga

Topics Economy

AI Achieves Atomic Precision in Antibody Design: A New Era for Drug Discovery Dawns

November 05, 2025

Seattle, WA – November 5, 2025 – In a monumental leap for biotechnology and artificial intelligence, Nobel Laureate David Baker’s lab at the University of Washington’s Institute for Protein Design...

Via TokenRing AI

Topics Artificial Intelligence Intellectual Property

Market Movers: Eli Lilly, Cadre, BP, Kellanova, and Teva Soar to 52-Week Highs Amidst Shifting Economic Tides

November 05, 2025

In a period marked by cautious optimism and strategic pivots, several prominent companies across diverse sectors have recently defied broader economic uncertainties to achieve significant 52-week...

Stanley Druckenmiller's firm bought Viking Therapeutics stock (VKTX) during Q2 at $25.33. Now up 36%, VKTX shows a Golden Cross.

Topics Economy Intellectual Property Supply Chain

Druckenmiller's Viking Trade Just Hit A Golden Cross — And A Sweet 36% Gain

November 05, 2025

Via Benzinga

Jim Cramer Says 'Take A Pass' On This Tech Stock, Won't Go Near Oils

November 05, 2025

Zoom Communications is a good company, Cramer says. Still, he advises, "take a pass." Plus: Viking Therapeutics, Profrac and Altria.

Via Benzinga

Citigroup Says This Obesity Drugmaker's Stock Is Now a Buy

November 05, 2025

The bank's lead analyst recognizes the importance of getting in early with potentially game-changing drug development.

A massive earnings beat sent shares rallying, but the latest GLP-1 treatment underperformed, while long-term debt is rising and profit margins are shrinking.

Eli Lilly And Company Stock Signal: Did Earnings Justify The Rally?

November 05, 2025

Via Talk Markets

Topics Earnings

Elanco (NYSE:ELAN) Surprises With Q3 Sales

November 05, 2025

Animal health company Elanco (NYSE:ELAN) reported Q3 CY2025 results topping the market’s revenue expectations, with sales up 10.4% year on year to $1.14 billion. Guidance for next quarter’s revenue was...

Lilly's GLP-1 drug became the best-selling drug on Earth in the third quarter.

This Company Now Has the World's No. 1 Drug. Should You Invest $1,000?

November 05, 2025

Can Novo Nordisk’s ‘Attractive’ Fundamentals Outweigh Slowing Wegovy Sales And A $149 Price Cap?

November 05, 2025

Novo Nordisk cut its 2025 profit and sales forecasts as slower GLP-1 growth and pricing pressure hit margins.

li Lilly stock saw a welcome improvement to its Relative Strength (RS) Rating on Wednesday, with an increase from 70 to 77.

Topics Lawsuit

Eli Lilly Stock Sees RS Rating Rise To 77

November 05, 2025

Via Investor's Business Daily

Earnings To Watch: Collegium Pharmaceutical (COLL) Reports Q3 Results Tomorrow

November 04, 2025

Pharmaceutical company Collegium Pharmaceutical (NASDAQ:COLL) will be announcing earnings results this Thursday before market open. Here’s what investors should know.